Insider Trading History of Hamilton Thomas Edward

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Hamilton Thomas Edward since 2019. This trader's CIK number is 1769848. At the time of last reporting, Hamilton Thomas Edward was the Director of Larimar Therapeutics, Inc.. (stock ticker symbol LRMR). Also see all insider trading activities at Larimar Therapeutics, Inc..

Note that in the past Hamilton Thomas Edward also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Larimar Therapeutics, Inc. (LRMR) by Hamilton Thomas Edward

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2024 LRMR 57,208 $499,997 0 $0 0 $0
2022 LRMR 317,460 $999,999 0 $0 0 $0

Yearly summary of insider trading at Annaly Capital Management Inc (NLY) by Hamilton Thomas Edward

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2021 NLY 0 $0 80,000 $734,400 0 $0
2020 NLY 200,000 $1,193,000 0 $0 0 $0
2019 NLY 90,000 $852,300 0 $0 0 $0


Insider trading activities at 2 companies by Hamilton Thomas Edward:

1. Larimar Therapeutics, Inc. (LRMR)

2. Annaly Capital Management Inc (NLY)

Table 1. Insider trading of Larimar Therapeutics, Inc. (LRMR) by Hamilton Thomas Edward

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2024-02-16 LRMR Buy 57,208 8.74 499,997
2022-09-16 LRMR Buy 317,460 3.15 999,999

Table 2. Insider trading of Annaly Capital Management Inc (NLY) by Hamilton Thomas Edward

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2021-05-03 NLY Sale 80,000 9.18 734,400
2020-05-15 NLY Buy 200,000 5.96 1,193,000
2019-05-17 NLY Buy 90,000 9.47 852,300

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hamilton Thomas Edward (Director of Larimar Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.